Economic evaluation of HBV vaccination: a systematic review of recent publications (2000-2013). by LA TORRE, Giuseppe et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=khvi20
Download by: [Universita Studi la Sapienza] Date: 27 April 2016, At: 02:00
Human Vaccines & Immunotherapeutics
ISSN: 2164-5515 (Print) 2164-554X (Online) Journal homepage: http://www.tandfonline.com/loi/khvi20
Economic evaluation of HBV vaccination:
A systematic review of recent publications
(2000-2013)
Giuseppe La Torre, Alice Mannocci, Rosella Saulle, Vittoria Colamesta,
Angela Meggiolaro, Daniele Mipatrini & Alessandra Sinopoli
To cite this article: Giuseppe La Torre, Alice Mannocci, Rosella Saulle, Vittoria Colamesta,
Angela Meggiolaro, Daniele Mipatrini & Alessandra Sinopoli (2016): Economic evaluation of
HBV vaccination: A systematic review of recent publications (2000-2013), Human Vaccines &
Immunotherapeutics, DOI: 10.1080/21645515.2016.1166328
To link to this article:  http://dx.doi.org/10.1080/21645515.2016.1166328
Accepted author version posted online: 22
Apr 2016.
Submit your article to this journal 
Article views: 4
View related articles 
View Crossmark data
 Economic evaluation of HBV vaccination: A systematic review of recent publications (2000-2013) 
Giuseppe La Torre*,1, Alice Mannocci, Rosella Saulle, Vittoria Colamesta, Angela Meggiolaro, Daniele Mipatrini, 
Alessandra Sinopoli 
1Department of Public Health and Infectious Diseases, Sapienza University of Rome 
*Address for correspondence: Prof. Giuseppe La Torre, Sapienza University of Rome, Piazzale Aldo Moro 5 – 00161 
Rome e-mail: giuseppe.latorre@uniroma1.it Tel. +39.06.49694308 
Abstract 
Aim: To conduct a systematic review of the economic evaluations (EE) of HBV vaccination, taking also into account the 
studies published in the new millennium. 
Methods: An extensive scientific literature review was conducted using two electronic medical journal databases: Scopus 
and PubMed engines for published studies on EE of HBV vaccination. 
Results: 22 articles were reviewed, 9, 5 and 8 cost-effectiveness, cost-benefit and cost-utility analysis, respectively. 
Studies were mainly concerning EE of universal vaccination (UV), mostly with regards to low or low-medium income 
countries. For high income countries, EE were focused on the possible implementation of HBV vaccination in particular 
settings, such as diabetic, renal and other chronic conditions care, as well as infectious diseases. 
UV has usually a very good cost-effectiveness ratio (80%), ranging from cost-saving (China) or few Euro per LY/QALY 
gained (in Thailand, and Vietnam) to 630.00$/QALY in USA (Asian and Pacific Islands). 
Moreover, EE of HBV vaccination are favorable in the infectious diseases field as well as for chronic conditions. In relation 
to diabetes the studies gave controversial results. 
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 Conclusion: This systematic review highlighted the importance of introducing HBV vaccination not only for infant UV 
program but also for other settings in which patients are people are affected by communicable and non-communicable 
diseases. 
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 Introduction 
It is well recognized that Hepatitis B virus (HBV) is one of world's most common blood-borne viral infection, chronically 
infecting hundreds of million people worldwide [1]. Moreover, there is evidence that it is responsible for substantial 
morbidity and mortality and is together with HCV a leading cause of hepatocellular carcinoma [1]. It is estimated that 
nearly 2 billion people worldwide have been infected with HBV; of these, 360 million are chronically infected, and among 
them 600000 individuals die each year from HBV associated liver cirrhosis or hepatocellular carcinoma [2]. 
According to Drummond [3] the economic evaluation can be defined as the comparative analysis of alternative courses of 
action in terms of both their costs and consequences, and the first attempts to consider economic issues related to HBV 
vaccination date back to early ’80 [4], and particular attention was posed on health care personnel (HCP) (i.e., renal 
dialysis, blood transfusion centres, clinical biology laboratories, surgery, anaesthesia, closed psychiatric institutions and 
others), finding that the financial investment has proved economically beneficial for the insurance fund. In fact, we must 
recognized that, since HBV is transmitted primarily through blood and sexual routes, in a way that is similar to HIV and 
hepatitis C virus (HCV) [5], it must be considered an occupational hazard for HCPs [6]. Moreover, according to Di 
Giuseppe et al [7] HCPs are at risk of blood-borne, airborne, and droplet-spread transmission of infectious agents, and 
this is particularly true due to frequent and often intensive occupational exposures, among which it can be included 
percutaneous injury, contact with mucous membranes, or nonintact skin with blood or other potentially infectious bodily 
fluids [8-10]. On the other hand , HCPs can also act as potential paths of nosocomial transmission of several infections to 
patients and other close contacts. 
Beutels underlined that in areas of low, intermediate and high endemicity of HBV infection, the universal vaccination 
seems justifiable on the basis of economic evaluation. However, he noted that the accuracy of the models has improved 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ita
 St
ud
i la
 Sa
pie
nz
a] 
at 
02
:00
 27
 A
pr
il 2
01
6 
 over the years, even if some improvements have been made, further steps are required, especially concerning 
transparency, completeness and comparability of analyses [11]. Furthermore, Tu et al. very recently reviewed this issue 
applied to developing and less developed countries, finding that the almost totality of the studies the implementation of 
universal immunization against HBV is capable to reduce the level of endemicity of hepatitis B, and probably cost effective 
in many settings [12]. 
As far as concerns infant vaccination importance, it is well known that infants infected with hepatitis B virus (HBV) face the 
risk of developing severe complications [13] and childhood chronic HBV infection prevalence has been markedly reduced 
in those counties where vaccination policies have been put in place [14-17]. 
In accordance with the World Health Organization [18] recommendations, all infants should receive their first dose of the 
hepatitis B vaccine immediately after birth, preferably within 24 hours. 
The availability of a vaccine against HBV infection let the disease effectively preventable in a safe and effective way since 
1982 [19]. As of 2011, hepatitis B vaccine has been incorporated in 179 countries’ national infant immunization programs, 
and about 69% of the 2008 birth cohort received all three doses of the vaccine [19]. Nevertheless, while the vaccination 
coverage of three doses at the world level is 75%, many differences do exist between countries and macro-areas (Table 
1), with lower coverage in South-East Asia (57%) and African (71%) WHO regions. 
At the beginning of the ’90 Bloom et al. [20] found that the strategy of universal newborn vaccination alone leads is cost-
effective (incremental cost-per-year-of-life saved of $3.332), and the same results were found by Holliday and Faulds [21]. 
However, other studies found that mass vaccination of adolescents were more cost-effective [22] or at least as cost-
effective as the universal vaccination for infants, over a wide range of assumptions [23], but no cost-saving [24]. 
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 Further, it was clear that the majority of the cost of HBV vaccination program is due to the cost of the vaccine (more than 
three fourth of the cost of introducing HBV vaccine) [25, 26]. 
Mass vaccination for health care workers was an issue since the availability of HBV vaccination, and this option was 
considered more beneficial than costly[27-29], and now must be considered all over the world also for ethical and social, 
as well as for economic aspects [30]. There is also evidence that preventing the transmission of HBV infections in dialysis 
centers is possible with the administration of HBV vaccine to susceptible patients and staff [31]. 
Essentially, the need to go beyond the infant universal vaccination, i.e. to vaccinate older age groups, including 
adolescents and adults, is determined by the burden of disease (HBV infection) in a specific country [32]. Italy was one of 
the first countries (1991) that, in order to reduce the HBV related pathologies in the Italian population, implemented a 
multi-level approach, including the universal vaccination of newborn babies, 12-year old adolescents and high risk groups 
[33]. The effect of this vaccination strategy was impressive, reaching two main goals, i.e., protecting susceptible people 
from the infection caused by the hepatitis B virus and reducing the virus circulation in the population [34]. 
Thus, the objective of this paper is to conduct a systematic review of the economic evaluations of HBV vaccination, taking 
also into account the studies published in the new millennium. 
Results 
Data extraction 
The information extracted were: references, publication year and type of analyses, alternatives, nation/ perspective, 
sample, efficacy measures/cost measure and results. The characteristics of each study are shown in Table 3. 
Identification of relevant research 
Using the aforementioned inclusion criteria the following articles were found (see Fig 1. Flow-chart): 
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 - 211 articles for Pubmed search; 
- 276 articles for Scopus search; 
A total of 487 articles were found for all strings, of which 392 were removed because were duplicates in two or all search 
engines. Moreover, 51 articles were excluded because they were not relevant. At the end of the evaluation, 44 articles 
met the pre-determined criteria described above, and 22 were included in the systematic review process [35-56]. 
Type of Economic evaluation of the included studies 
The 22 articles reviewed are shown in Table 2. 
The classification of the studies is based on the type of economic evaluation: 
- CEA (cost-effectiveness analysis) was performed in 9 economic evaluation studies [36, 38-40, 43, 44, 47, 50, 53]; 
- CBA (cost-benefit analysis) was evaluated by 5 studies [35, 37, 46, 48, 51]; 
- CUA (cost-utility analysis) was considered in 8 studies [41, 42, 44, 49, 52, 54-56]. 
The population and the countries considered were different in the studies: 5 analyses were conducted in Europe 
(Bulgaria, Germany, Ireland and UK), 8 in America (all in the USA), 7 in Asia (China, Iran, South Korea Taiwan, Thailand, 
Vietnam), 1 in Africa (Mozambique) and 1 in Oceania (Australia). 
Sample and results 
The majority of the studies were concerning economic analysis of universal vaccination (12; 54.5%), mostly with regards 
to low or low-medium income countries (7; 58.3%). Moreover, it is interesting to note that in studies on high income 
countries, the economic evaluations were focused on the possible implementation of HBV vaccination in particular 
settings, such as diabetic, renal and other chronic conditions care, as well as infectious diseases (Sexually transmitted 
diseases, HIV counseling, HCV patients, injection drug users). 
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 So the results of this systematic review are heterogeneous. Concerning the universal vaccination, this has usually a very 
good cost-effectiveness ratio (80%), ranging from cost-saving (China) [56] or few Euro per LY/QALY gained (in Thailand, 
and Vietnam) [40, 52] to 630.00 $ /QALY in USA (Asian and Pacific Islands) [42]. 
There is clear evidence that all infants should receive their first dose of hepatitis B vaccine as soon as possible after birth, 
preferably within 24 hours [2]. 
As suggested by WHO the universal HBV vaccination represents a comprehensive approach to eliminating HBV 
transmission that considers infections acquired perinatally and during early childhood, but it is important to consider also 
other settings that involve different pattern of transmissions and different populations (teenagers and adults) [2]. In fact, as 
far as concerns the other settings, the economic evaluations of HBV vaccination are favourable in the infectious diseases 
field as well as for chronic conditions. The HBV vaccination could be of great interest and impact in settings that involve 
injection drug users (IDUs) and jails, where HBV infections could be present and rapidly spreading [57-58], alone or 
together to other viruses (HIV, HCV). In this cases, the accelerated vaccination schedule could easily improve hepatitis B 
vaccination adherence among IDUs [59], as well as the use of the standard vaccine regimen (0, 1, 6 months) is capable to 
may induce higher levels of antibody to the virus comparable to those induced by regimens of four injections of either 
standard or double doses [60]. 
In relation to diabetes the economic evaluations gave controversial results, reflecting what happens for the clinical 
recommendation. In 2011, the Advisory Committee on Immunization Practices (ACIP) recommended that all previously 
unvaccinated adults aged between 19 and 59 years with diabetes mellitus (both type 1 and 2) be vaccinated against 
hepatitis B as soon as possible after a diagnosis of diabetes is made (recommendation category A). On the other hand, 
data on the risk for hepatitis B among adults aged 60 years and over are less robust, so that this group of patients could 
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 be vaccinated at the discretion of the treating clinician, only after the assessment of the risk and the likelihood of an 
adequate immune response to vaccination [61]. Concerning the economic evaluations, while Kuan et al [55] found an 
acceptable incremental C/E (12.613$/QALY),this did not happen for Hoerger et al [54]. 
As far as concerns the quality of these economic evaluations, using the weighted scale of Drummond, very high scores 
were found (median 91.5; range: 53-98) with the vast majority of the papers (90.9%) with score over 80 (Table 2). 
Discussion 
In this systematic review a wide range of results in terms of economic evaluations of HBV vaccination was found, 
especially regarding the way for measuring the efficacy/effectiveness. From the methodological point of view, cost-utility 
and cost-effectiveness analysis are almost equally represented. In order to be more adherent to commonly used cost-
utility analysis performed in the biomedical field, future studies will address better the way in incorporating a quality 
weighted measure of effectiveness, such as QALY (Quality Adjusted Life Years). This kind of studies will be of crucial 
importance in order to convince decision makers to implement the HBV vaccination programs in the public sector. 
Moreover, in this review we found five single studies in which costs and effectiveness were measured in the same way 
(money), and this is in line with the actual trends of the economic evaluations that use less frequently cost-benefit 
analysis. 
Concerning possible limitation of this study, it must be recognized that there is a lack of information in many 
countries/continents, considering that a single study exists coming from Africa and no one from Southern and Central 
America. Anyway, this is not surprising, given the very low number of randomized clinical trial conducted in these 
continents [62-68]. 
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 Some final considerations must be underlined. Since Hepatitis B infection and related diseases are considered an 
important hazard for the general population and for many workers, not only in the health sector, the economic impact is 
relevant (69-70). 
There is evidence that the virus transmission usually occurs through blood as well as blood products, and other body 
fluids (saliva, semen, et cetera). Different situations could be the case of transmission, such as sexual intercourse, illicit 
drug use with shared needles, above all heroin, blood transfusions or use of blood products. Moreover, HBV infection is 
one of the mail virus transmitted by medical practices, such as surgical intervention, dental care, especially in cases 
where infection control precautions are inadequate (71-80). 
The infections sustained by HBV mainly affect the liver, causing acute and chronic diseases, such as liver infections and 
cirrhosis (73). 
It is now well known that chronic infections with HBV hepatitis C virus (HCV) are also considered the main cause of liver 
cancer and for this fact classified by the International Agency for Research on Cancer (IARC) as carcinogenic to humans 
(group 1) (74). 
According to WHO forecast, the infections caused by HBV will be the third cause of death for infectious diseases in 2030 
in the industrialized countries (75). Viral hepatitis, and among which those caused by HBV, knows no borders (76). 
The epidemiology of HBV related pathologies is continuously changing. As a typical example the waste management field 
is a field of increasing interest, considering the vulnerability of recyclable general waste collectors to HBV infection, as 
well as the medical waste handlers. There is sufficient evidence that witnesses HBV immunization, as well as post-
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 exposure protection of medical waste handlers, in addition to proper management of medical waste by the health 
authorities, might reduce the risk of acquiring infectious agents by this type of workers in a significant way (77). 
Additionally, we must consider in this field also that the need to use HBV vaccine prophylaxis in this category of workers is 
important for avoid possible medical legal litigations (78-79). 
In this field the importance of public health policies that address the health and safety of this socially vulnerable population 
is very high (80-82). 
A very recent systematic review highlights that waste workers need to be vaccinated against HBV infection taking into 
account these workers are at risk of acquiring this infection through the exposure to potentially infected waste (83). 
The HBV vaccination has also and indirect effect on the epidemiology of blood transmitted diseases (BTD). In fact, there 
is evidence that significant improvements in the screening process of BTD of both donors and household contacts is 
fundamental in order to minimize the infectious risk (84-85). 
Moreover, a very good field for reducing the HBV burden through the HBV vaccination is concerning men who have sex 
with men, and Commercial sex workers, among which there exist a disproportionate burden of hepatitis B virus (HBV) 
infections (86-95). 
The WHO recommendations include the offer the rapid HBV vaccination regimen for persons who inject drugs (96-97). 
As far as concerns one of the strengths of this review, a gap has been filled, since it was shown the use of economic 
evaluations n highly endemic areas, that was lacking in previous reviews [11], and this is very important to raise both 
public awareness of the effectiveness and economic attractiveness of universal immunization against HBV [52]. 
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 Conclusion 
In conclusion, this systematic review highlighted the importance of introducing HBV vaccination not only for infant 
universal vaccination program but also for other settings in which patients are people are affected by communicable and 
non-communicable diseases. 
HBV infection causes at the world level a high burden in terms of costs, both direct and indirect (987-120). 
In accordance with Beutels [11] it must be recognized that the role of economic evaluations of HBV vaccination in the 
decision-making process could be important, but the economic evaluation is only one of several elements that can have 
an influence on the introduction of a specific vaccine policy in a given country, including issues such as medical, 
epidemiological, organizational and ethical aspects. There is sufficient evidence that, after the cases of HPV (121-123), 
influenza and pneumococcal vaccinations (124-125), there is the need for a full health technology assessment (HTA) 
(126) also for HBV vaccination. As suggested by NICE international (127), HTA should always be part of the priority-
setting process, and this is particularly true in the field of vaccinations, in order to give efficient and equitable allocation of 
health care in the field of prevention. 
Materials and methods 
Identification of relevant studies 
A scientific literature review was conducted considering the period 2000-2013 and using two electronic medical journal 
databases: Scopus and PubMed engines for published studies on economic evaluations of HBV vaccination. 
The keywords used were the following: 
“HBV”, “vaccination”, “cost-effectiveness”, “cost utility”, “cost-effectiveness”, “cost benefit” and “economic evaluation”. 
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 Search criteria and the flow-chart of the results are summarized in Figure 1. 
No date and language restrictions were applied for the selection of the papers published. Further, all studies focused on 
the economic evaluation of HBV vaccination were selected, without any limitation of population and country. 
The review process, including search and selection (identification, screening, eligibility of included studies) was performed 
according to the PRISMA criteria [128] (Figure 1). 
In the selection process, abstracts were initially read to identify potentially eligible full text papers which were then 
retrieved and assessed in order to decide on the final inclusion. 
Articles were examined and were excluded if: 
1) the research was based on considering costs only; 
2) studies were not pertaining to HBV vaccination; 
3) the full text was not available. 
If the electronic databases outcomes overlapped, all duplicate articles were eliminated. 
The weighted Drummond’s checklist (129) was used to assess the quality of the economic evaluations. 
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 Table 1 - HBV Vaccination coverage estimates, by vaccine and World Health Organization (WHO) region — worldwide, 
2011 
WHO region 
Vaccination coverage (%) 
3 doses of hepatitis B vaccine 
Worldwide 75 
African 71 
Americas 90 
Eastern Mediterranean 83 
European 77 
South-East Asia 56 
Western Pacific 91 
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 Table 2. Characteristics of the selected studies by year of publication and types of economic analysis 
References Type of 
analyses 
Alternatives Nation/ 
Perspective 
Sample Efficacy 
Measures/ 
cost 
measures 
Main Results Quality assessment 
score 
Wiewiora-
Pilecka 
2000 [35] 
CBA -universal 
vaccination of all 
neonates 
- no vaccination 
Poland Cohort 
followed for a 
20-years 
period  
-Costs 
-Benefit 
In a period of 20 
years 
-no vaccination: loss 
of 6.318,3 million€ 
(26.484,2 million 
zlotys) 
- vaccination: 
benefits of €2.873,9 
million€ (12.046.4 
million zlotys) and 
losses of 3.444,3 
million€ (14.437 
million zlotys) 
53 
Harris al 
2001[36] 
CEA 1.High-risk infants 
vaccination (65% 
compliance) 
2. universal infant 
vaccination with 
Hib-HBV vaccine  
Australia A Markov 
model 
simulated the 
natural 
history of 
HBV infection 
1.Direct cost 
2.Incremental 
cost per life 
year gained 
Incremental cost per 
life year gained = 
11.862 $ 
91 
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  and 
disease in an 
Australian 
birth cohort 
(260.000) 
Yang et al 
2001[37] 
CBA -Prevention 
(Vaccination, 
antibody tests, 
immunoglobulin) 
- Treatment of 
HBV-related 
diseases 
South 
Korea/societal 
perspective 
Costs paid in 
1997 
Direct and 
indirect costs 
Prevention costs: 
142.239 million Won 
Direct cost for 
disease: 710.502 
million Won 
Indirect cost for 
disease: 225.575 
89 
Saab et al 
2002[38] 
CEA -routine, annual 
administration of 
the vaccine 
booster to all 
hemodialysis 
patients (non-
screening 
strategy) 
- vaccination 
based on anti-
HBs titers 
USA hypothetical 
population 
of 1000 
hemodialysis 
patients 
followed for 5 
years 
-costs  
-
effectiveness 
(i.e. number 
of HBV 
infections 
prevented) 
the mean cost per 
patient prevented: 
-in the screening 
strategy US$ 261 
- in the non-
screening strategy 
US$ 1129 
76 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ita
 St
ud
i la
 Sa
pie
nz
a] 
at 
02
:00
 27
 A
pr
il 2
01
6 
 (screening 
strategy) 
Adibi et al. 
2004 [398] 
CEA  1.HBsAg 
screening to find 
those would-be 
couples one of 
whom is HBsAg + 
and putting 
seronegative 
subjects on a 
protection protocol 
comprising HBV 
vaccination, single 
dose HBIG and 
condom protection 
2.as above plus 
HBcAb screening 
in the HBsAg 
negative spouses 
of the HBsAg 
positive persons 
and giving the 
protocol only to 
HBcAb negative 
Iran/ societal and 
healthcare system 
Not reported cost of each 
chronic 
infection 
averted 
strategies 1: 202$ 
per chronic infection 
averted  
strategies2: 197$ 
per chronic infection 
averted 
86 
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 ones 
Vimolket et 
al 2005 
[40] 
CEA -screening for 
HBsAg, and 
vaccination (S1) 
-screening for 
HBsAg, then 
HBeAg, and 
vaccination (S2) 
-universal 
vaccination of all 
neonates (S3) 
- no vaccination 
Thailand A 
hypothetical 
cohort of 
newborns 
-Costs 
-case 
prevented 
Cost-effectiveness 
per case prevented  
-for Strategy 1: € 
6.63 (292.79 baht)  
-for Strategy 2: € 
5.99 (264.34 baht) 
-for Strategy 3: € 
3.42 (151.05 baht) 
85 
Kim et al 
2006 [41] 
CUA -routine 
vaccination 
without screening 
(V) 
- screening for 
antibody to 
hepatitis B core 
antigen with an 
initial vaccine 
dose during 
the first visit (SV1) 
- screening and 
USA/ societal 
perspective 
Two 
hypothetical 
cohorts of 
100,000 
adults 
attending  
HIV 
counseling 
and testing 
sites 
-Cost per 
QALY gained  
-Cost per life 
year gained  
 
ICER 
V = $4400 both per 
QALY gained and 
per life year gained 
compared with no 
vaccination 
SV1 and SV2 = 
dominated 
compared with no 
vaccination 
92 
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 vaccination based 
on screening 
results(SV2) 
-no intervention 
Hutton et 
al 2007 
[42] 
CUA -Status quo 
-Universal 
vaccination (UV) 
-Screen and Treat 
(ST) 
- Screen Treat 
and Vaccinate 
(STV) 
-Screen Treat and 
Ring Vaccinate 
(STRV) 
USA Hypothetical 
cohort of 10 
000 Persons 
in Asian and 
Pacific 
Islands 
Costs (2006 
U.S. dollars), 
quality-
adjusted 
life-years 
(QALYs), and 
incremental 
cost-
effectiveness 
ICER 
UV = US$ 630.000 
ST = US$36.000 
STV = US$ 388.000 
STRV = US$ 40.000 
98 
Jakiche et 
al 2007[43] 
CEA -universal 
vaccination with 
the combined 
HAV and HBV 
vaccine 
-selective 
vaccination based 
on immunity 
determined by 
blood testing 
USA/Health care 
systems 
Patients with 
HCV 
infection 
belonging to 
the New 
Mexico 
Veterans 
Affairs health 
care system 
-direct 
medical costs 
(2004 US$)  
- the 
effectiveness 
measure was 
the number 
of patients 
immune to 
both HAV 
ICER 
universal strategy: 
$154 per additional 
patient immune to 
HAV and HBV 
93 
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 and HBV 
Tilson et al 
2007[44] 
CEA - universal 
administration of 
HBV vaccine to all 
infants 
-no vaccination 
Ireland/national 
healthcare system 
The Markov 
model of 
HBV infection 
is run over a 
total of  80 
cycles of 1 
year each. A 
period of 80 
years was 
chosen as 
the lifetime 
period 
-Costs 
-Life years 
gained 
incremental cost 
effectiveness ratio  
-for the lowest price 
of vaccine (€16.65 
per course): ICER 
€10.992/life years 
gained (LYG) 
-for the highest 
price of vaccine 
(€58.44 per course): 
ICER €67.200/LYG 
90 
Hu et al 
2008 [45] 
CUA -standard 
vaccination (0,1, 6 
months) 
-accelerated 
vaccination (0,1, 2 
months) 
-no vaccination  
USA/healthcare 
sector 
Cohort of 
1964 
injection drug 
users (IDUs) 
-Direct costs 
-Qality-
Adjusted Life 
Years 
(QALY) 
All vaccination 
strategies were cost-
saving compared to 
the no-vaccination 
strategy one more 
than 70% od IDUs 
had access to 
medical care 
92 
 Miriti et al 
2008[46] 
CBA - routine hepatitis 
B vaccination 
policy at STD 
USA (California 
and Colorado) 
Hypothetical 
cohort of 2 
million STD 
-Direct and 
indirect costs 
-Benefits 
Costs 
-vaccination 
program: $138 
94 
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 clinics  
-no vaccination 
clinic clients 
accessing 
services in 
one year 
million 
-HBV infections 
occurring: $878 
million 
-clients’ time and 
travel would cost 
$45 million 
Benefits 
The net economic 
benefit (savings) of 
routine vaccination 
would be $526 
million 
Hung et al 
2009 [47] 
CEA -universal 
vaccination 
-no vaccination 
Taiwan/healthcare 
payer and societal 
perspectives 
Simulation of 
a birth cohort 
using 
300.000 
newborns in 
1984 
Incremental 
cost-
effectiveness 
ratio (ICER)-
per life year 
gained 
- QALY 
gained 
(ICUR) 
The vaccination 
program dominated 
over a no-
vaccination program, 
i.e., it is less costly 
and more effective 
Societal perspective: 
ICER= -14.190; 
ICUR= -13.238 
Health care 
perspective: ICER= -
6.126; ICUR = -
96 
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 5.715  
Fischinger 
et al 2010 
[48] 
CBA 1.mandatory HBV 
testing (A1) 
2. A1 + nucleic 
acid testing (A2) 
3. A1 + individual 
donation testing 
(A3) 
4. Time-
dependant HBV 
vaccination (B1) 
5. Titre dependent 
booster 
vaccination (B2) 
6. A1 + B2 
Germany 231 whole 
blood donors 
and 126 
apheresis 
donors 
1.Direct costs 
 
A1 over 20 years  = 
€1009 million (base-
case) 
A2 incremental costs 
of 43% 
A3 incremental costs 
of 339% 
B1 cost reductions 
relative to A1 of 30% 
(cost-saving) 
B2 cost reductions 
relative to A1 of 14% 
(cost-saving) 
B3 incremental costs 
of 70% 
92 
Siddiqui et 
al 2011 
[49] 
CUA -Universal infant 
vaccination 
-Adolescent 
vaccination 
-No vaccination 
UK 
UK lifetime 
cohort 
-costs 
-QALYs 
Universal infant 
vaccination: £260,000 
per QALY gained 
Adolescent vaccination: 
£493,000 per QALY 
gained 
95 
Klingler et 
al 2012 
[50] 
CEA -existing 
vaccination 
schedule 
Mozambique Birth cohort 
of 2008 
-Cost 
-Disability-
adjusted life 
ICER 
-for the additional 
birth dose of 250.95 
94 
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 administered at 6–
10–14 weeks  
-a birth dose 
vaccination in 
addition to the 
existing 
vaccination 
schedule 
years 
(DALYs) 
averted 
US$ per DALY 
averted  
-sensitivity analysis: 
72 US$/DALY averted -
683 US$/DALY averted 
Savova et 
al 2012 
[51] 
CBA - cost of 
immunisation 
- cost of acute and 
chronic cases 
therapy 
(hospitalization +  
ambulatory 
pharmacotherapy) 
Bulgaria Real cases 
between 
1992 and 
2010 
-costs 
- Net health 
benefit 
(Invested – 
Averted) 
Net health benefit for 
acute and chronic 
cases 
Whole period:€ 
14292 (BGN 
27927035) 
Last 10 years: € 70 
(BGN  136854)   
87 
Tu et al 
2012 [52] 
CUA - universal 
administration of 
HBV vaccine to all 
infants 
-no vaccination 
Vietnam/ national 
healthcare system 
Simulation 
with a 
Vietnamese 
birth 
cohort using 
1,639,000 
newborns in 
2002 
-Costs 
- Life years 
gained 
-QALY 
-HBV carrier 
averted 
ICER per LYG (US 
$) from payer’s 
perspective: 4.52 
ICER per QALY 
gained (US $) from 
payer’s perspective: 
3.77 
Cost of preventing a 
HBV carrier: 41.79 
89 
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 Chen et al 
2013 [53]  
CEA - universal 
vaccination 
(strategy V); 
- V plus screening 
for hepatitis B 
surface antigen 
(HBsAg) and 
HBIG treatment 
for HBsAg-
positive mothers' 
neonates 
(strategy S) 
-V plus screening 
for hepatitis B 
e-antigen 
(HBeAg), HBIG 
for HBeAg-
positive mothers' 
neonates 
(strategy E); 
- V plus screening 
for HBsAg then 
HBeAg, HBIG for 
Taiwan Hypothetical 
cohort of 
neonates of 
carrier 
mothers 
-costs 
-infection 
averted 
Strategy S: <$4000 
per infection averted 
for carrier rates >5%.  
Strategy V: $1400 
per infection averted 
at 30% carrier rate; 
$3100 per infection 
averted at 5% carrier 
rate 
91 
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 all HBeAg-
positive, and 
some HBeAg-
negative/HBsAg-
positive mothers' 
neonates 
(strategy S&E) 
Hoerger et 
al 2013 
[54]  
CUA -vaccination of  
diabetes patients 
aged 20-59 years 
- vaccination of  
diabetes patients 
aged 60 years 
and over 
 
USA Unvaccinated 
cohort of 
patients with 
diabetes  
1.Direct cost 
2.acute and 
chronic HBV 
infections 
and 
complications 
3.QALY 
 
Incremental cost-
effectiveness ratio: 
-vaccinating 20-59 
years old: US$ 
75.094/QALY 
vaccinating over 60 
years old: US$ 2.7 
million/QALY 
88 
Kuan et al 
2013 [55] 
CUA -vaccination with 
HEPLISAV  
-vaccination with 
Engerix-B 
USA/payer 
perspective 
Hypothetical 
populations: 
diabetics, 
patients with 
chronic or 
end stage 
kidney 
disease, 
healthcare 
workers and 
-Costs 
- QALY 
 
ICER 
Diabetic patients: 
US$ 12.613 
Patients with chronic 
kidney disease: 
dominant 
Patients with end-
stage renal disease: 
dominant 
Health care workers: 
92 
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 international 
travelers to 
countries 
with high 
HBV infection 
prevalence 
US$ 11.062 
Travellers: US$ 
5.564 
Lu et al 
2013 [56] 
CUA -universal 
newborn 
vaccination 
comprising a 
timely birth dose 
(HepB1)  
- universal 
newborn 
vaccination with 
three-doses 
(HepB3)  
- no vaccination 
China/ societal or 
health care payer 
perspective 
cohort of 
10,000,000 
infants born 
in 2002 
-Costs  
- Life years 
- QALY 
Cost saving both for 
societal or health 
care payer 
perspective  
95 
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Figure 1 
Records removed because duplicates: 392 
Full text articles assessed for eligibility: 44 
Not appropriate full text articles: 22 
Records included in the  
 
 101 
11
70 
Records removed because not pertinent: 51 
Records identified through Scopus  
search 
 
 HBV vaccination AND 
economic evaluation: 24 
 HBV vaccination AND cost 
utility: 4 
 HBV vaccination AND cost 
effectiveness: 135 
 HBV vaccination AND cost 
benefits: 113 
 
Records screened on basis of title and abstract: 95 
Records identified through PubMed  
search 
 
 HBV vaccination AND 
economic evaluation: 33 
 HBV vaccination AND cost 
utility: 2 
 HBV vaccination AND cost 
effectiveness: 96 
 HBV vaccination AND cost 
benefits: 80 
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